Plasma is a vital part of your circulatory system. It is the liquid portion of the blood. Health professionals use it to make the therapies that treat life-threatening, chronic and genetic diseases. Plasma is the essential groundwork for for a wide range of life-saving and health enhancing medicines. Plasma donors are always needed, but a number of deciding factors determine who can donate and when they can donate.
Your background history of illness may prevent you from donating plasma. If you have a serious or chronic condition that may affect the quality of your plasma, you will not be able to donate. This includes conditions such as syphilis, HIV or Hepatitis types A, B and C.
Rules for Donating Plasma
Donation centers require that all donors be in acceptable physical condition before they donate any plasma. In the United States, all potential plasma donors are required to submit to a pre-donation physical screening to test their general health. Potential donors are also tested for any transmittable viruses. During this screening, blood will be drawn to check the body's total plasma protein levels, to ensure the donor has effective plasma suitable for donation.
- Donation centers require that all donors be in acceptable physical condition before they donate any plasma.
- In the United States, all potential plasma donors are required to submit to a pre-donation physical screening to test their general health.
Women who have been pregnant at any time cannot donate plasma. Pregnant women are at risk to develop what is known as transfusion related acute lung injury, or TRALI. TRALI is not completely understood, but is normally related to blood transfusion patients. It is believed to be associated with antibodies that the body produces during blood transfusions or in this case, pregnancy. Any woman who has been or is currently pregnant will not be allowed to donate plasma for her own safety.
- Women who have been pregnant at any time cannot donate plasma.
Requirements to Donate Plasma
There is a frequency limit to donating plasma. The human body can typically replace plasma within 24 to 48 hours. This depends on the donor keeping a healthy diet that includes the proper amount of proteins, vitamins and fluids. Federal regulations limit a plasma donor to only two times per week. Within a seven-day period he may donate twice, with two days in between the donations.
- There is a frequency limit to donating plasma.
- Federal regulations limit a plasma donor to only two times per week.
Rules for Donating Plasma
Requirements to Donate Plasma
What Is a CBC With Auto Diff Blood Test?
What Is the Big E Antibody?
Side Effects From a Blood Transfusion
Why Do People Pass Out While Giving Blood?
What Is a Biometric Screening?
Hepatic Encephalopathy Low-Protein Diet
What Causes a Low Blood Count?
- Bobati SS, Naik KR. Therapeutic Plasma Exchange - An Emerging Treatment Modality in Patients with Neurologic and Non-Neurologic Diseases. J Clin Diagn Res. 2017;11(8):EC35-EC37. doi:10.7860/JCDR/2017/27073.10480
- Cleveland Clinic. Plasmaphoresis in MS.
- Ehler J, Koball S, Sauer M, et al. Response to therapeutic plasma exchange as a rescue treatment in clinically isolated syndromes and acute worsening of multiple sclerosis: A retrospective analysis of 90 Patients. PLoS ONE. 2015;10(8):e0134583. doi:10.1371/journal.pone.0134583
- Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the writing committee of the American Society for Apheresis: The seventh special issue. Journal of Clinical Apheresis. 2016;31(3):149-338. doi:10.1002/jca.21470
- USFDA. Coronavirus (COVID-19) update: Daily roundup, March 24, 2020. Updated March 24, 2020.
- Mount Sinai. Mount Sinai to begin the transfer of COVID-19 antibodies into critically ill patients. Updated March 24, 2020.
- Michigan State University. National COVID-19 Convalescent Plasma Project.
- USFDA. Recommendations for investigational COVID-19 convalescent plasma. Updated April 13, 2020.
- Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice—Evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. Journal of Clinical Apheresis. 2010;25:83-177. doi:10.1002/jca.20240
- Ehler J, Blechinger S, Rommer PS, et al. Treatment of the first acute relapse following therapeutic plasma exchange in formerly glucocorticosteroid-unresponsive Multiple Sclerosis patients-A nulticenter study to evaluate glucocorticosteroid responsiveness. Int J Mol Sci. 2017;18(8). doi:10.3390/ijms18081749
- Bobati SS, Naik KR. Therapeutic plasma exchange - An emerging treatment modality in patients with neurologic and non-neurologic diseases. J Clin Diagn Res. 2017;11(8):EC35-EC37. doi:10.7860/JCDR/2017/27073.10480
- UT Southwestern Medical Center. Therapeutic plasma exchange.
- Shemin D, Briggs D, Greenan M. Complications of therapeutic plasma exchange: a prospective study of 1,727 procedures. J Clin Apher. 2007;22(5):270-6. doi:10.1002/jca.20143
- Lu J, Zhang L, Xia C, Tao Y. Complications of therapeutic plasma exchange: A retrospective study of 1201 procedures in 435 children. Medicine (Baltimore). 2019;98(50):e18308. doi:10.1097/MD.0000000000018308
- Saint Luke's. Understanding therapeutic plasma exchange (TPE).
- Beth Israel Lahey Health Winchester Hospital. Plasmapheresis. Updated August 21, 2018.
- Szczeklik W, Wawrzycka K, Włudarczyk A, et al. Complications in patients treated with plasmapheresis in the intensive care unit. Anaesthesiol Intensive Ther. 2013;45(1):7-13. doi:10.5603/AIT.2013.0002
- Kaplan AA, Fridey JL. Therapeutic apheresis (plasma exchange or cytapheresis): Complications. UpToDate. March 2020.
- Harris ES, Meiselman HJ, Moriarty PM, Metzger A, Malkovsky M. Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis. Journal of Scleroderma and Related Disorders. 2018;3(2):132-152. doi:10.1177/2397198318758606
- Ehler J, Blechinger S, Rommer PS, et al. Treatment of the First Acute Relapse Following Therapeutic Plasma Exchange in Formerly Glucocorticosteroid-Unresponsive Multiple Sclerosis Patients-A Multicenter Study to Evaluate Glucocorticosteroid Responsiveness. International Journal of Molecular Sciences. 2017;18(8):1749. Published 2017 Aug 11. doi:10.3390/ijms18081749.
- Harris ES, Meiselman HJ, Moriarty PM, Metzger A, Malkovsky M. Therapeutic Plasma Exchange for the Treatment of Systemic Sclerosis: A Comprehensive Review and Analysis. Journal of Scleroderma and Related Disorders. 2018;3(2):132–152. doi:10.1177/2397198318758606.
- Kaplan AA, Fridey JL. Therapeutic Apheresis (Plasma Exchange or Cytapheresis): Complications. UpToDate. Updated August 2, 2018. https://www.uptodate.com/contents/therapeutic-apheresis-plasma-exchange-or-cytapheresis-complications.
- Olek MJ, Howard J. Treatment of Acute Exacerbations of Multiple Sclerosis in Adults. UpToDate. Updated October 9, 2018. https://www.uptodate.com/contents/treatment-of-acute-exacerbations-of-multiple-sclerosis-in-adults.
- Panayiota P, Ben-Hur T, Adi Vaknin D, Oded A, Dimitrios K. Clinical Efficacy of Plasma-Exchange in Patients With Progressive Forms of Multiple Sclerosis and NMO-Spectrum Disease. Journal of Multiple Sclerosis. 2016;3:181. doi:10.4172/2376-0389.1000181.
- Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. Journal of Clinical Apheresis. 2016;31(3):149–62. doi:10.1002/jca.21470.
Located in southeastern Kentucky, Charles Judd began writing semi-professionally in early 2005 for local publications. His work has been published in his hometown newspapers, the "Jackson Sun" and the "Jackson Times." He has many diverse interests and enjoys writing about various subjects. Charles holds a Bachelor of Science in industrial machine technology.